Chemokine receptor CXCR5 supports solitary intestinal lymphoid tissue formation, B cell homing, and induction of intestinal IgA responses.
Solitary intestinal lymphoid tissue (SILT) comprises a spectrum of phenotypically diverse lymphoid aggregates interspersed throughout the small intestinal mucosa. Manifestations of SILT range from tiny lymphoid aggregates almost void of mature lymphocytes to large structures dominated by B cells. Large SILT phenotypically resemble a single Peyer's patch follicle, suggesting that SILT might contribute to intestinal humoral immune responses. In this study, we track the fate of individual SILT in vivo over time and analyze SILT formation and function in chemokine receptor CXCR5-deficient mice. We show that, in analogy to Peyer's patches, formation of SILT is invariantly determined during ontogeny and depends on CXCR5. Young CXCR5-deficient mice completely lack SILT, suggesting that CXCR5 is essential for SILT formation during regular postnatal development. However, microbiota and other external stimuli can induce the formation of aberrant SILT distinguished by impaired development of B cell follicles in CXCR5-deficient mice. Small intestinal transplantation and bone marrow transplantation reveal that defect follicle formation is due to impaired B cell homing. Moreover, oral immunization with cholera toxin or infection with noninvasive Salmonella fail to induce efficient humoral immune responses in CXCR5-deficient mice. Bone marrow transplantation of CXCR5-deficient recipients with wild-type bone marrow rescued B cell follicle formation in SILT but failed to restore full humoral immune responses. These results reveal an essential role of CXCR5 in Peyer's patch and SILT development and function and indicate that SILT do not fully compensate for the lack of Peyer's patches in T cell-dependent humoral immune responses.
Velaga
Sarvari
S
Institute of Immunology, Hannover Medical School, Hannover, Germany.
Herbrand
Heike
H
Friedrichsen
Michaela
M
Jiong
Tian
T
Dorsch
Martina
M
Hoffmann
Matthias W
MW
Förster
Reinhold
R
Pabst
Oliver
O
D000284:Administration, Oral; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D016026:Bone Marrow Transplantation / Q000276:immunology; D002634:Chemotaxis, Leukocyte / Q000276:immunology*; D002772:Cholera Toxin / Q000627:therapeutic use; D007070:Immunoglobulin A / Q000096:biosynthesis*; D007413:Intestinal Mucosa / Q000276:immunology* / Q000378:metabolism; D008221:Lymphoid Tissue / Q000254:growth & development / Q000276:immunology* / Q000378:metabolism; D008231:Lymphopenia / Q000235:genetics / Q000276:immunology / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D054380:Receptors, CXCR5 / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D012481:Salmonella Infections, Animal / Q000276:immunology / Q000473:pathology; D012486:Salmonella typhimurium / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
C513179:CXCR5 protein, mouse; D007070:Immunoglobulin A; D054380:Receptors, CXCR5; D002772:Cholera Toxin